GOG3005-ABB VIE Protocol M13-694: A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Gynecologic Oncology Group
Start Date
November 1, 2015
End Date
January 31, 2024
Administered By
Duke Cancer Institute
Awarded By
Gynecologic Oncology Group
Start Date
November 1, 2015
End Date
January 31, 2024